<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36917918</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Metabolic alterations precede neurofilament changes in&#xa0;presymptomatic ALS gene carriers.</ArticleTitle><Pagination><StartPage>104521</StartPage><MedlinePgn>104521</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">104521</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2023.104521</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(23)00086-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The emergence of potentially effective new therapies for genetic forms of amyotrophic lateral sclerosis (ALS) necessitates the identification of biomarkers to facilitate early treatment, prior to the onset of motor symptoms. Here, we sought to investigate whether metabolic alterations are detectable in presymptomatic ALS gene mutation carriers, and whether such alterations precede neurofilament light chain (NfL) changes in serum.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Between 02/2014 and 11/2021, we prospectively studied 60 presymptomatic ALS gene mutation carriers (40% male, age 48.7&#xa0;&#xb1;&#xa0;14.9; 28 C9orf72, 22 SOD1, 10 other) compared to 73 individuals from the same families (47%&#xa0;male, age 47.4&#xa0;&#xb1;&#xa0;12.9) without pathogenic mutations as controls. Bioimpedance analysis (BIA) and indirect calorimetry were performed, and Body Mass Index (BMI), Fat Mass (FM), Body Fat Percentage, Body Water (BW), Lean Body Mass (LBM), Extracellular Mass (ECM), Body Cell Mass (BCM), ECM/BCM ratio, Cells Percentage, Phase Angle, Resting Metabolic Rate (RMR), Metabolic Ratio (MR), and NfL were measured. Participants and evaluators were blinded regarding gene carrier status.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Presymptomatic ALS gene carriers showed reduced LBM (p&#xa0;=&#xa0;0.02), BCM (p&#xa0;=&#xa0;0.004), Cells Percentage (p&#xa0;=&#xa0;0.04), BW (p&#xa0;=&#xa0;0.02), Phase Angle (p&#xa0;=&#xa0;0.04), and increased ECM/BCM ratio (p&#xa0;=&#xa0;0.04), consistently indicating a loss of metabolically active body cells. While in C9orf72 mutation carriers all tissue masses were reduced, only metabolically active tissue was affected in SOD1 mutation carriers. Unexpectedly, RMR (p&#xa0;=&#xa0;0.009) and MR (p&#xa0;=&#xa0;0.01) were lower in presymptomatic ALS gene carriers compared to non-carriers. NfL serum levels were similar in mutation carriers and non-carriers (p&#xa0;=&#xa0;0.60).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">The observed metabolic phenomena might reflect reduced physical activity and/or preemptive, insufficient compensatory mechanisms to prepare for the later hypermetabolic state. As pre-symptomatic biomarkers we propose ECM/BCM ratio and Phase Angle for SOD1, and a 4-compartment affection in BIA for C9orf72 mutation carriers.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">This work was an investigator-initiated trial. On the German side, there was no institutional or industrial funding. On the Swedish side, this work was supported by grants from the Swedish Brain Foundation (grants nr. 2013-0279, 2016-0303, 2018-0310, 2020-0353), the Swedish Research Council (grants nr. 2012-3167, 2017-03100), the Knut and Alice Wallenberg Foundation (grants nr. 2012.0091, 2014.0305, 2020.0232), the Ulla-Carin Lindquist Foundation, Ume&#xe5; University (223-2808-12, 223-1881-13, 2.1.12-1605-14) and the V&#xe4;sterbotten County Council (grants nr 56103-7002829), King Gustaf V:s and Queen Victoria's Freemason's Foundation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dorst</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany; German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany. Electronic address: johannes.dorst@uni-ulm.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weydt</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease and Gerontopsychiatry/Neurology, University of Bonn Medical Center, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany; German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witzel</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandler</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huss</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany; German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiesenfarth</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knehr</LastName><ForeName>Antje</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nther</LastName><ForeName>Kornelia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Human Genetics, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weishaupt</LastName><ForeName>Jochen H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Neurodegenerative Disorders, Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neurosciences, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudlo</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Rostock University Medical Center, and German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forsberg</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Science, Neurosciences, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Clinical Science, Neurosciences, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenbohm</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuster</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany; German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roselli</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany; German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupuis</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Inserm, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute for Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tumani</LastName><ForeName>Hayrettin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany; German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kassubek</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany; German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany; German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Metabolic</Keyword><Keyword MajorTopicYN="N">Metabolism</Keyword><Keyword MajorTopicYN="N">Mutations carriers</Keyword><Keyword MajorTopicYN="N">Presymptomatic</Keyword></KeywordList><CoiStatement>Declaration of interests JD reports honoraria for presentations from Biogen and ITF Pharma. PW reports grants or contracts from Alle Lieben Schmidt e.V., Boris Canessa Stiftung, and EHDN; consulting fees from Biogen, ITF Pharma, and Novartis. DB reports stocks from Ionis pharmaceuticals. PMA reports consultancies or advisory boards for Biogen, Roche, Avrion, Regeneron, uniQure and Orphazyme; clinical trial site investigator for Biogen, Alexion, Sanofi, Lilly AL-S Pharma, Amylyx, PTC Pharmaceuticals, Orion Pharma and Orphazyme; since 1993 Director of the ALS-genetic laboratory at Ume&#xe5; University Hospital that performs clinical and research genetic testing; member of the ClinGen ALS Gene Curation Expert panel. LD reports grants from Cytokinetics and Lecture Fees from Cytokinetics. ACL reports grants or contracts from European Union (Horizon), BMBF, Deutsche Forschungsgemeinschaft (DFG), and Deutscher Akademischer Austauschdienst (DAAD) as well as sponsored trials by Amylyx, Ferrer International, Novartis Research and Development, Mitsubishi Tanabe, Apellis Pharmaceuticals, Alexion, Orion Pharma, Biogen, and Orphazyme; payment for talks from Biologix, the German Society of Neurology, Biogen, Springer Medicine, Amylyx, and Streamed Up! GmbH; support for attending meetings and/or travel from Biogen; participation on advisory boards from Roche Pharme, Biogen, Alextor, and Amylyx; President of Deutsche Neurowissenschaftliche Gesellschaft (NWG). All other authors report no conflicts of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>10</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>19</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36917918</ArticleId><ArticleId IdType="pmc">PMC10024076</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2023.104521</ArticleId><ArticleId IdType="pii">S2352-3964(23)00086-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brettschneider J., Del Tredici K., Toledo J.B., et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20&#x2013;38. Epub 2013/05/21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport J.C., Preux P.M., Magy L., et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr. 2001;74(3):328&#x2013;334. Epub 2001/08/28.</Citation><ArticleIdList><ArticleId IdType="pubmed">11522556</ArticleId></ArticleIdList></Reference><Reference><Citation>Janse van Mantgem M.R., van Eijk R.P.A., van der Burgh H.K., et al. Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population-based study. J&#xa0;Neurol Neurosurg Psychiatry. 2020;91(8):867&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pubmed">32576612</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter R.S., Rosenbohm A., Dupuis L., et al. Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia. Eur J Epidemiol. 2017;32(10):901&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">28975435</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Corcia P., Fergani A., et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70(13):1004&#x2013;1009. Epub 2008/01/18.</Citation><ArticleIdList><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia K., Witzel S., Witzel C., et al. Mutation-specific metabolic profiles in presymptomatic amyotrophic lateral sclerosis. Eur J Neurol. 2022;28(10)</Citation><ArticleIdList><ArticleId IdType="pubmed">36169607</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat P.F., Bruneteau G., Gordon P.H., et al. Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(1-2):166&#x2013;171. Epub 2010/02/27.</Citation><ArticleIdList><ArticleId IdType="pubmed">20184518</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J., Kuhnlein P., Hendrich C., Kassubek J., Sperfeld A.D., Ludolph A.C. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J&#xa0;Neurol. 2011;258(4):613&#x2013;617. Epub 2010/12/04.</Citation><ArticleIdList><ArticleId IdType="pubmed">21128082</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A.C., Dorst J., Dreyhaupt J., et al. Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol. 2019;17(10)</Citation><ArticleIdList><ArticleId IdType="pubmed">31849093</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills A.M., Hubbard J., Macklin E.A., et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;383(9934):2065&#x2013;2072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4176708</ArticleId><ArticleId IdType="pubmed">24582471</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J., Doenz J., Kandler K., et al. Fat-rich versus carbohydrate-rich nutrition in ALS: a randomised controlled study. J&#xa0;Neurol Neurosurg Psychiatry. 2022;93(3):298&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">35022317</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J., Schuster J., Dreyhaupt J., et al. Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis. J&#xa0;Neurol Neurosurg Psychiatry. 2020;91(9):1007&#x2013;1009. Epub 2020 Aug 11.</Citation><ArticleIdList><ArticleId IdType="pubmed">32788256</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N&#xa0;Engl J Med. 2020;383(2):109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M. American Neurological Association Annual Meeting (virtual); 2021. Results from the phase 3 VALOR study and its open-label extension: evaluating the clinical efficacy and safety of tofersen in adults with ALS and confirmed SOD1 mutation.</Citation></Reference><Reference><Citation>Steinacker P., Feneberg E., Weishaupt J., et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J&#xa0;Neurol Neurosurg Psychiatry. 2016;87(1):12&#x2013;20. Epub 2015/08/25.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Lombardi V., Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84(1):130&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P., Oeckl P., Huss A., et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. 2016;79(1):152&#x2013;158. Epub 2015/11/04.</Citation><ArticleIdList><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;299. Research Group on Motor Neuron Diseases. Epub 2001/07/24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S., Aziz N., Bale S., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the association for molecular pathology. Genet Med. 2015;17(5):405&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller S., Preische O., Sohrabi H.R., et al. Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. Sci Rep. 2017;7(1):1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5430642</ArticleId><ArticleId IdType="pubmed">28450713</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchholz A.C., Bartok C., Schoeller D.A. The validity of bioelectrical impedance models in clinical populations. Nutr Clin Pract. 2004;19(5):433&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">16215137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruperto M., Barril G. The extracellular mass to body cell mass ratio as a predictor of mortality risk in hemodialysis patients. Nutrients. 2022;14(8):1659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9029814</ArticleId><ArticleId IdType="pubmed">35458220</ArticleId></ArticleIdList></Reference><Reference><Citation>Staufer K., Halilbasic E., Hillebrand P., et al. Impact of nutritional status on pulmonary function after lung transplantation for cystic fibrosis. United European Gastroenterol J. 2018;6(7):1049&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6137582</ArticleId><ArticleId IdType="pubmed">30228893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott M., Fischer H., Polat H., et al. Bioelectrical impedance analysis as a predictor of survival in patients with human immunodeficiency virus infection. J&#xa0;Acquir Immune Defic Syndr Hum Retrovirol. 1995;9(1):20&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">7712230</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport J.C., Marin B., Funalot B., Preux P.M., Couratier P. Phase angle is a prognostic factor for survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9(5):273&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">18720089</ArticleId></ArticleIdList></Reference><Reference><Citation>Haugen H.A., Chan L.N., Li F. Indirect calorimetry: a practical guide for clinicians. Nutr Clin Pract. 2007;22(4):377&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">17644692</ArticleId></ArticleIdList></Reference><Reference><Citation>Weir J.B. New methods for calculating metabolic rate with special reference to protein metabolism. 1949. Nutrition. 1990;6(3):213&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">2136000</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris J.A., Benedict F.G. A&#xa0;biometric study of human basal metabolism. Proc Natl Acad Sci U S A. 1918;4(12):370&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1091498</ArticleId><ArticleId IdType="pubmed">16576330</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A., Peter R., Dorst J., et al. Life course of physical activity and risk and prognosis of amyotrophic lateral sclerosis in a German ALS registry. Neurology. 2021;97(19):e1955&#x2013;e1963.</Citation><ArticleIdList><ArticleId IdType="pubmed">34670816</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport J.C., Preux P.M., Truong T.C., Vallat J.M., Sautereau D., Couratier P. Nutritional status is a prognostic factor for survival in ALS patients. Neurology. 1999;53(5):1059&#x2013;1063. Epub 1999/09/25.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496266</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J., Cypionka J., Ludolph A.C. High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(7-8):533&#x2013;536. Epub 2013/08/16.</Citation><ArticleIdList><ArticleId IdType="pubmed">23944684</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>